CDKN2A and neoplasm: CDK4 is amplified or overexpressed in various epithelial malignancies, sarcomas, gliomas, breast tumors, lymphomas, and melanoma.293,317 A specific mutation identified in melanomas, CDK4 R24C, renders CDK4 insensitive to INK4 inhibition and correlates with tumor development.